Biopharmaceutical outsourcing services provider PCI Pharma Services (PCI) has reached an agreement to purchase clinical trial supply services provider Sherpa Clinical Packaging to expand its US operational footprint.

The acquisition is expected to support PCI’s clinical trial supply services portfolio and will add additional capabilities to support customers from the early phases of clinical development through to commercial launch.

Sherpa was founded in 2010 to provide clinical packaging services for the biopharmaceutical companies on the West Coast.

Equipped with cold chain technologies, it offers primary and secondary packaging, as well as labelling for Phase I-IV studies, distribution, storage and returns.

PCI’s CEO Salim Haffar said: “The acquisition of Sherpa is the next logical step in our clinical services expansion strategy, further enhancing our development-stage capabilities and geographic presence.”

PCI’s services include contract development and manufacturing, clinical supply and commercial packaging services.

“The acquisition of Sherpa is the next logical step in our clinical services expansion strategy.”

Over the last 12 months, the company has been engaged in expanding its global clinical services business, with Sherpa set to become its third acquisition during the period.

Other acquisitions include Irish contract packaging services company Millmount Healthcare and Australian firm Pharmaceutical Packaging Professionals (PPP).

Sherpa founder and CEO Mark Paiz said: “Sherpa’s success is due in large part to our commitment to deliver customers the highest levels of service, quality and reliability.

“I strongly believe PCI will continue to build on our success, as well as enhance Sherpa with its global network and market-leading reputation.”

The acquisition of Sherpa will add two more facilities to PCI’s network of 18 good manufacturing practice (GMP) facilities in seven locations.

Free Whitepaper How electronic inspection sensors prevented a potentially extremely costly product recall

A pharmaceutical client was at risk of a product recall due to a capping problem with a new tablet formulation. This document explains how DJA Pharma prevented a costly recall with a simple, elegant and effective solution.

Enter your details here to receive your free whitepaper.

Machinery whitepaper

Download our whitepaper

Yes I have read and accept the terms and conditions and privacy policys.


You are in control of the communications you receive from us and you can update your preferences anytime to make sure you are receiving information that matters to you. Please check our Verdict Privacy Policy to see how we protect and manage your submitted data.

You will receive your free whitepaper after you submit the form.

Close